



Asmanex HFA[®] (mometasone furoate) – Expanded indication, new strength

- On August 12, 2019, the [FDA approved](#) Merck's [Asmanex HFA \(mometasone furoate\)](#) inhalation solution, for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.
 - Asmanex HFA was previously approved for this indication in patients 12 years and older.
 - Asmanex HFA is NOT indicated for the relief of acute bronchospasm
- The FDA also approved an Asmanex HFA 50 mcg strength (per actuation) for use in pediatric patients aged 5 to less than 12 years. Asmanex HFA was previously available in a 100 mcg and 200 mcg strength.
- The approval of Asmanex HFA's expanded indication was based on a 12-week, double-blind study in 583 patients aged 5 to less than 12 years with persistent asthma. Patients were randomized to Asmanex HFA 50 mcg dose, two other doses of Asmanex HFA, [Asmanex dry-powder inhaler](#) or placebo.
 - Primary endpoint results show that after 12 weeks of treatment, Asmanex HFA 50 mcg was statistically superior to placebo with respect to the improvement from baseline in AM pre-dose percent predicted FEV₁ at the end of the dosing interval (6.29%, 95% CI: 3.05, 9.53).
- The recommended dose of Asmanex HFA for the maintenance treatment of asthma in patients aged 5 to less than 12 years is two inhalations of Asmanex HFA 50 mcg twice daily. The maximum daily dosage is 200 mcg.
 - Refer to the Asmanex HFA drug label for dosing for patients 12 years and older.
- Merck's launch plans for the 50 mcg strength of Asmanex HFA are pending.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.